UK life sciences venture capital firm Syncona is launching Quell Therapeutics with a $43m (£34m) investment. The start-up will seek to develop regulatory T cell therapies to treat immune system diseases. Quell will use immune cell therapies for non-cancer diseases, including type 1 diabetes, rheumatoid arthritis and inflammatory bowel disease, as well as solid organ transplant rejection.
UK life sciences venture capital firm Syncona is launching Quell Therapeutics with a £34m ($43m) investment. The start-up will seek to develop regulatory T cell therapies to treat immune system diseases. Quell will use immune cell therapies for non-cancer diseases, including type 1 diabetes, rheumatoid arthritis and inflammatory bowel disease, as well as solid organ transplant rejection.